

# PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novo Nordisk A/S	02/04/2011
RECEIVING PARTY DATA	
Name:	BioGeneriX AG
Street Address:	Janderstrasse 3
City:	Mannheim
State/Country:	GERMANY
Postal Code:	68199
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12162952
CORRESPONDENCE DATA	
Fax Number:	(312)616-5700
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	312-616-5600
Email:	assignments@leydig.com
Correspondent Name:	Leydig, Voit & Mayer, Ltd.
Address Line 1:	Two Prudential Plaza, Ste. 4900
Address Line 2:	180 N. Stetson
Address Line 4:	Chicago, ILLINOIS 60601-6731
ATTORNEY DOCKET NUMBER:	707148
NAME OF SUBMITTER:	John Kilyk, Jr.
Total Attachments: 1 source=US12_162952[Leydig707148]Assignment#page1.tif	

CH \$40.00 12162952

501426431

PATENT  
 REEL: 025744 FRAME: 0039

Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza  
Suite 4900  
Chicago, Illinois 60601-6731

## ASSIGNMENT

**WHEREAS**, Novo Nordisk A/S of Novo Alle, 2880 Bagsværd, Denmark (hereinafter referred to as Assignor) owns a certain invention entitled:

### MODIFICATIONS OF CST-II FOR INCREASED PROTEIN EXPRESSION

for which invention an application was executed for a U.S. patent, which was filed on December 5, 2008, and accorded U.S. Application No. 12/162,952 (hereinafter referred to as Patent Property); and


**WHEREAS**, BioGeneriX AG of Janderstrasse 3, 68199 Mannheim, Germany (hereinafter referred to as Assignee) is desirous of acquiring the entire right, title, and interest in, to, and under the Patent Property.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor assigns and transfers to the Assignee and the Assignee's legal representatives, successors, and assigns the full and exclusive rights in, to, and under the Patent Property as well as any reissue or reexamination thereof. Assignor authorizes and requests the U.S. Patent and Trademark Office to issue any such reissue or reexamination to the Assignee in accordance with the terms of this Assignment.


**ASSIGNOR DOES HEREBY COVENANT** and agree with the Assignee that it will not execute any writing or do any act conflicting with the terms of this Assignment and that Assignor will, upon request and at Assignee's expense, execute such additional documents and do such additional acts as may be necessary to perfect the Assignee's enjoyment of this Assignment.

**IN WITNESS WHEREOF**, Assignor has caused one of its officers to hereunder set his/her hand on the date shown below.

Date 1 FEBRUARY 2011

  
\_\_\_\_\_  
Name of Officer: Kåre Schultz  
Chief Operating Officer  
Title of Officer: Novo Nordisk A/S

Date 1 FEBRUARY 2011

  
\_\_\_\_\_  
Name of Officer: Jesper Brandgaard  
Chief Financial Officer  
Title of Officer: Novo Nordisk A/S